68 related articles for article (PubMed ID: 19783361)
21. Inhibition of the met receptor in mesothelioma.
Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
[TBL] [Abstract][Full Text] [Related]
22. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
23. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
24. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells.
Liu Y; Yang Y; Ye YC; Shi QF; Chai K; Tashiro S; Onodera S; Ikejima T
J Pharmacol Sci; 2012; 118(4):423-32. PubMed ID: 22466960
[TBL] [Abstract][Full Text] [Related]
25. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
[TBL] [Abstract][Full Text] [Related]
26. Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.
Leiser D; Pochon B; Blank-Liss W; Francica P; Glück AA; Aebersold DM; Zimmer Y; Medová M
FEBS Lett; 2014 Mar; 588(5):653-8. PubMed ID: 24440350
[TBL] [Abstract][Full Text] [Related]
27. Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.
Gual P; Giordano S; Anguissola S; Comoglio PM
Oncogene; 2001 Sep; 20(39):5493-502. PubMed ID: 11571647
[TBL] [Abstract][Full Text] [Related]
28. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF
J Pathol; 2009 Jul; 218(3):399-408. PubMed ID: 19402129
[TBL] [Abstract][Full Text] [Related]
29. Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK.
Zhen Y; Sørensen V; Jin Y; Suo Z; Wiedłocha A
Oncogene; 2007 Sep; 26(44):6372-85. PubMed ID: 17533378
[TBL] [Abstract][Full Text] [Related]
30. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.
Long IS; Han K; Li M; Shirasawa S; Sasazuki T; Johnston M; Tsao MS
Mol Cancer Res; 2003 Mar; 1(5):393-401. PubMed ID: 12651912
[TBL] [Abstract][Full Text] [Related]
31. Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis.
Day RM; Cioce V; Breckenridge D; Castagnino P; Bottaro DP
Oncogene; 1999 Jun; 18(22):3399-406. PubMed ID: 10362361
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase).
Lecour S; Suleman N; Deuchar GA; Somers S; Lacerda L; Huisamen B; Opie LH
Circulation; 2005 Dec; 112(25):3911-8. PubMed ID: 16344382
[TBL] [Abstract][Full Text] [Related]
33. MET oncogene inhibition as a potential target of therapy for uveal melanomas.
Abdel-Rahman MH; Boru G; Massengill J; Salem MM; Davidorf FH
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3333-9. PubMed ID: 20164465
[TBL] [Abstract][Full Text] [Related]
34. [Construction of a recombinant stable Ba/F3 cell strain containing Tpr-Met].
Shu LF; Li W; Zhan YQ; Xu WX; Yang XM; Li CY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1151-3. PubMed ID: 23127403
[TBL] [Abstract][Full Text] [Related]
35. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
Koon EC; Ma PC; Salgia R; Welch WR; Christensen JG; Berkowitz RS; Mok SC
Int J Gynecol Cancer; 2008; 18(5):976-84. PubMed ID: 18021219
[TBL] [Abstract][Full Text] [Related]
36. Met receptor inhibitor SU11274 localizes in the endoplasmic reticulum.
Wiest EJ; Smith HJ; Hollingsworth MA
Biochem Biophys Res Commun; 2018 Jul; 501(4):858-862. PubMed ID: 29752941
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation.
Kucerova L; Demkova L; Skolekova S; Bohovic R; Matuskova M
BMC Cancer; 2016 May; 16():308. PubMed ID: 27175734
[TBL] [Abstract][Full Text] [Related]
38. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.
Gao W; Bing X; Li M; Yang Z; Li Y; Chen H
Med Oncol; 2013 Jun; 30(2):546. PubMed ID: 23536000
[TBL] [Abstract][Full Text] [Related]
39. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.
Voortman J; Harada T; Chang RP; Killian JK; Suuriniemi M; Smith WI; Meltzer PS; Lucchi M; Wang Y; Giaccone G
Curr Pharm Des; 2013; 19(5):833-40. PubMed ID: 22973954
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.
Lui VW; Wong EY; Ho K; Ng PK; Lau CP; Tsui SK; Tsang CM; Tsao SW; Cheng SH; Ng MH; Ng YK; Lam EK; Hong B; Lo KW; Mok TS; Chan AT; Mills GB
Oncogene; 2011 Mar; 30(9):1127-34. PubMed ID: 21057531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
